top of page
Recent Posts

FDA Gives Priority Review to Tovorafenib in Pediatric Low-Grade Glioma

The FDA has granted priority review to a new drug application (NDA) for single-agent tovorafenib (DAY101) as a treatment for those with relapsed or progressive pediatric, low-grade glioma, according to a press release from Day One Biopharmaceuticals.

Search By Tags
bottom of page